Recurrent or Refractory Pediatric Ependymoma Clinical Trial
— PETEYOfficial title:
A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
| Verified date | June 2019 |
| Source | Astellas Pharma Inc |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.
| Status | Terminated |
| Enrollment | 25 |
| Est. completion date | November 26, 2012 |
| Est. primary completion date | November 26, 2012 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year to 21 Years |
| Eligibility |
Inclusion Criteria: - Recurrent of refractory ependymoma or subependymoma - Performance Status (PS): Lansky = 50% for patients = 10 years of age or Karnofsky = 50% for patients >10 years of age - Measurable disease, defined as 1 measurable lesion that can be accurately measured in 2 planes that has not received radiation therapy within 12 weeks - Recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy - = 1 year to = 21 years - Serum creatinine for patients = 5 years in age is = 0.8 mg/dL or Creatinine Clearance/Glomerular Filtration Rate (GFR) = 70 mL/min/m^2 - Serum creatinine for patients > 5 and = 10 years in age is = 1.0 mg/dL or Creatinine Clearance/GFR = 70 mL/min/m^2 - Serum creatinine for patients > 10 and = 15 years in age is = 1.2 mg/dL or Creatinine Clearance/GFR = 70 mL/min/m^2 - Serum creatinine for patients > 15 years in age is = 1.5 mg/dL or Creatinine Clearance/GFR = 70 mL/min/m^2 - Total bilirubin is = 1.5 x upper limit of normal for age - Alanine aminotransferase (ALT) = 3 x upper limit of normal - Absolute neutrophil count > 1000/µL - Platelet count > 100,000/µL - Hemoglobin > 8 gm/dL - Neurologically stable for at least 7 days prior to randomization - If receiving corticosteroids, patients must be on a stable or decreasing dose for at least 7 days before randomization - Patients of reproductive potential must agree to proactive effective contraceptive measures for the duration of the study and for at least 90 days after completion of study drug Exclusion Criteria: - Previously received epidermal growth factor receptor (EGFR)-targeted therapy - Previously received oral etoposide - Received craniospinal radiotherapy within 24 weeks prior to randomization - Received field radiotherapy to the target lesion within 12 weeks prior to randomization - Received symptomatic metastatic disease within 14 days prior to randomization - Received myelosuppressive chemotherapy within 21 days before randomization - Received growth factors within 7 days prior to randomization - Participating in another investigational drug trial - Received a biologic agent within 7 days prior to randomization - Received a monoclonal antibody within 28 days prior to randomization - Taking cytochrome P450 (CYP)3A4 or CYP1A2 inhibitors/inducers within 14 days prior to randomization - Taking proton pump inhibitors within 14 days prior to randomization - Smoking during treatment - Pregnant or breast-feeding females |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Strollery Children's Hospital Division of Hematology/Oncology | Edmonton | Alberta |
| Canada | Hospital for Sick Children | Toronto | Ontario |
| Canada | Children's and Women's Health Center of BC Division of Hematology/ Oncology/ BMT | Vancouver | British Columbia |
| United Kingdom | Birmingham Children's Hospital | Birmingham | |
| United Kingdom | Royal Hospital for Sick Children | Glasgow | |
| United Kingdom | Paediatric Oncology and Haematology Offices | Leeds | |
| United Kingdom | Alder Hey Children's NHS Foundation Trust Department of Oncology | Liverpool | |
| United Kingdom | Royal Manchester Children's Hospital Ward 84 | Manchester | |
| United Kingdom | University of Nottingham Children's Brain Tumour Research Centre | Nottingham | |
| United Kingdom | Royal Marsden Hospital | Sutton | |
| United States | Emory University Children's Healthcare of Atlanta Aflac Cancer Center & Blood Disorders | Atlanta | Georgia |
| United States | Children's Hospital Center for Cancer and Blood Disorders | Aurora | Colorado |
| United States | Johns Hopkins University School of Medicine | Baltimore | Maryland |
| United States | University of Alabama at Birmingham Dept. of Pediatric-Hematology/Oncology | Birmingham | Alabama |
| United States | Dana-Farber Cancer Institute Department of Pediatric Neuro-oncology | Boston | Massachusetts |
| United States | Children's Medical Center, Dallas Center for Cancer and Blood Disorders | Dallas | Texas |
| United States | Penn State Hershey Children's Hospital | Hershey | Pennsylvania |
| United States | University of Wisconsin Pediatric Hematology/Oncology Department | Madison | Wisconsin |
| United States | University of Miami | Miami | Florida |
| United States | Amplatz Children's Hospital University of Minnesota Medical Center- Pediatric Hematology Oncology | Minneapolis | Minnesota |
| United States | Columbia University Children's Hospital of New York Presbyterian Child & Adolescent Oncology Center | New York | New York |
| United States | Steven D Hassenfeld Children's Center - New York University | New York | New York |
| United States | Children's Hospital of Orange County (CHOC) | Orange | California |
| United States | Stanford University and Lucile Packard Children's Hospital | Palo Alto | California |
| United States | Center for Cancer and Blood Disorders-Phoenix Children's Hospital | Phoenix | Arizona |
| United States | Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania |
| United States | Oregon Health & Sciences University Doembecher Children's Hospital | Portland | Oregon |
| United States | Children's National Medical Center - D.C. Center for Cancer and Blood Disorders | Washington | District of Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| OSI Pharmaceuticals |
United States, Canada, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of Participants With an Objective Response | Objective response is defined as a best overall response of complete response (CR) or partial response (PR), evaluated using modified International Society of Pediatric Oncology Brain, Tumor Subcommittee for the Reporting of Trials criteria. Response was confirmed at least 28 days after the first assessment where the response criteria were met. Response was assessed by magnetic resonance imaging (MRI) every 8 weeks. CR: Complete disappearance of all enhancing tumor and mass effect On a stable or decreasing dose of corticosteroids (or receiving only adrenal replacement doses) Stable or improving neurologic examination sustained for = 4 weeks If cerebral spinal fluid (CSF) evaluation was positive, it must become negative (confirmed at least 2 times at consecutive samplings). PR: = 50% reduction in tumor size by bi-dimensional measurement On a stable or decreasing dose of corticosteroids Stable or improving neurologic examination sustained for = 4 weeks. |
From randomization until the end of treatment. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Duration of Response | Duration of response (complete or partial response [CR/PR]) was defined as the time from the date of the first documented response (CR/PR) to the first documented progression or death due to underlying cancer. If a participant had not progressed or died, the duration of overall response was censored at the date of last adequate disease assessment. Duration of response was only defined for participants whose best overall response was CR or PR. Progression was defined as a worsening of neurologic status that could not be explained by other causes, a > 25% increase in tumor size, the appearance of new lesions or CSF positivity, or increasing doses of corticosteroids required to maintain stable status. |
From randomization until the end of treatment. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Percentage of Participants With a Minor Response | Participants with a best overall response of minor response (MR), defined as: = 25% to < 50% reduction in tumor size by bi-dimensional measurement On a stable or decreasing dose of corticosteroids Stable or improving neurologic examination sustained for = 4 weeks. |
From randomization until the end of treatment. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Percentage of Participants With Disease Control | Disease control is a best overall response of CR or PR or MR or Stable disease (SD). CR: Complete disappearance of all enhancing tumor and mass effect On a stable or decreasing dose of corticosteroids Stable or improving neurologic examination sustained for = 4 weeks If CSF evaluation was positive, it must become negative (confirmed at least 2 times consecutively). PR: = 50% reduction in tumor size by bi-dimensional measurement On a stable or decreasing dose of corticosteroids Stable or improving neurologic examination sustained for = 4 weeks. MR: = 25% to < 50% reduction in tumor size by bi-dimensional measurement On a stable or decreasing dose of corticosteroids Stable or improving neurologic examination sustained for = 4 weeks. SD: Neurologic examination is at least stable Maintenance corticosteroid dose is not increased MRI meets neither the criteria for minor response nor for progressive disease Sustained for = 8 weeks. |
From randomization until the end of treatment. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Progression Free Survival (PFS) | Progression-free survival was defined as the time from randomization to disease progression based on central nervous system (CNS)-specific evaluation criteria as assessed by the investigator or death due to any cause, whichever occurs first. Participants did not progress or die before the data cutoff date for analysis were censored at the date of last disease assessment (including both radiologic assessment and neurologic assessment) where non-progression was documented. If a participant received any further anticancer therapy without prior documentation of disease progression, the participant was censored at the date of last disease assessment before starting new anti-cancer treatment. Participants were also censored at the date of last disease assessment with no documented progression if patients discontinued treatment for undocumented progression, toxicity or other reason before the data cutoff date for analysis. |
From randomization until the end of treatment. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Percentage of Participants With Prolonged Stable Disease | Prolonged stable disease (SD) was defined as SD with a duration of at least 16 weeks. The percentage of participants with prolonged SD was defined as participants who achieved a best overall response of CR or PR or MR or SD, and did not progress within 16 weeks from randomization. Progression was defined as a worsening of neurologic status that could not be explained by other causes, a > 25% increase in tumor size, the appearance of new lesions or CSF positivity, or increasing doses of corticosteroids required to maintain stable status. | From randomization until the end of treatment. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Duration of Stable Disease | Duration of stable disease (SD; defined as participants with an overall best response of complete, partial or minor response or stable disease) was defined as the time from the date of randomization to the first documented progression or death due to underlying cancer. If a participant had not progressed or died, the duration of SD was censored at the date of last adequate disease assessment. Duration of SD was only defined for participants whose best overall response was CR or PR or MR or SD. Progression was defined as a worsening of neurologic status that could not be explained by other causes, a > 25% increase in tumor size, the appearance of new lesions or CSF positivity, or increasing doses of corticosteroids required to maintain stable status. |
From randomization until the end of treatment. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Overall Survival (OS) | Overall survival was defined as the time from the date of randomization until the documented date of death. Participants who were still alive by the data cutoff date for analysis were censored on the last day the participant was known to be alive. | From randomization up to 12 months after the last dose. Median duration of follow-up was 12.9 months for erlotinib and 14.4 months for etoposide. | |
| Secondary | Safety Assessed Through Evaluation of Physical Exams, Vital Signs, Clinical Laboratory Tests and Adverse Events (AEs) | An AE was defined as any untoward medical occurrence in a study participant and did not necessarily have a causal relationship with study treatment. Clinically significant vital sign assessments, findings on physical or neurological examination, and laboratory findings associated with signs and/or symptoms requiring withdrawal, dose modification or medical intervention were recorded as AEs. An AE was considered serious if it resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a patient who received study drug or other important medical events. The relationship of each AE to study drug was assessed as either related or not related. |
From the date of first dose of study drug until 30 days after the last dose. The median time on treatment was 52 days for erlotinib and 58 days for etoposide. | |
| Secondary | Area Under the Curve From Time 0 to 24 Hours Post-dose for Erlotinib | Pharmacokinetic parameters were determined from the serial plasma concentration data obtained for erlotinib. Area under the plasma concentration-time curve from time zero to 24 hours (the dosing interval) measured at steady state using sparse sampling. | Day 14 predose and 0.5 to 1.5 hours, 2 to 3 hours and 4 to 8 hours post-dose. | |
| Secondary | Maximum Observed Plasma Concentration of Erlotinib (Cmax) | Pharmacokinetic parameters were determined from the serial plasma concentration data obtained for erlotinib. Maximum observed plasma concentration of erlotinib (Cmax) was measured at steady state on Day 14 using sparse sampling. | Day 14 predose and 0.5 to 1.5 hours, 2 to 3 hours and 4 to 8 hours post-dose. | |
| Secondary | Time to Maximum Observed Plasma Concentration of Erlotinib (Tmax) | Pharmacokinetic parameters were determined from the serial plasma concentration data obtained for erlotinib. Time to the maximum observed plasma concentration of erlotinib (Tmax) was measured at steady state on Day 14 using sparse sampling. | Day 14 predose and 0.5 to 1.5 hours, 2 to 3 hours and 4 to 8 hours post-dose. | |
| Secondary | Apparent Body Clearance (CL/F) of Erlotinib | Pharmacokinetic parameters were determined from the serial plasma concentration data obtained for erlotinib. Apparent body clearance (CL/F) of erlotinib was measured at steady state on Day 14 using sparse sampling. | Day 14 predose and 0.5 to 1.5 hours, 2 to 3 hours and 4 to 8 hours post-dose. | |
| Secondary | Apparent Volume of Distribution (Vz/F) of Erlotinib | Pharmacokinetic parameters were determined from the serial plasma concentration data obtained for erlotinib. The apparent volume of distribution (Vz/F) of erlotinib was measured at steady state on Day 14 using sparse sampling. | Day 14 predose and 0.5 to 1.5 hours, 2 to 3 hours and 4 to 8 hours post-dose. |